Peter Dow
Registered Senior Member
(Note to mods. I'm not sure if this is the medical science forum, if not, please move thread as appropriate).
Suggesting a scientific approach and method for the medical treatment of tumorous cancer.
Summary
A scientific approach and method for the medical treatment and cure for tumorous cancer disease is suggested and described.
The desired performance characteristics of suitable types of biological agents and pharmaceutical drugs and an appropriate method of employing those agents and drugs for the treatment and cure of cancer is described.
Caution
Neither the selection of specific agents and drugs, nor the determination of the optimal treatment regimes are described herein because the details for how best to implement the author's general approach and method to cure cancer still require further research by the scientific and medical community which it is hoped this scientific paper will inform and inspire.
So the reader should be cautioned that the author does not herein publish detailed suggestions for oncologists to prescribe for their cancer patients which pills to pop when. The author is a scientist who is trying to find a cure for everyone one day, not a doctor who can cure someone today.
Invitation to informed discussion
This is claimed to be a realistic scientific paper, not a snake-oil-style cure-all claim. This may not be obvious to everyone because I am an amateur independent scientist, neither employed as a scientist, nor published in traditional scientific journals.
I have published widely on the internet on mostly non-scientific topics and I am accustomed to debating my ideas on-line and so I’m quite comfortable inviting replies perhaps as helpful comments and criticisms from fellow scientists and I can also take questions from any cancer specialists, doctors or other informed parties who take an educated interest in such matters.
Approach and method
One type of biological agent and 3 types of drugs are utilised in 2 distinct treatment phases, perhaps with an intermission between phase 1 and phase 2 of the treatment to review that the goals of phase 1 treatment have been reached before moving on to phase 2.
Treatment Phase 1
It is proposed that phase 1 use a mild anaerobic biological agent (with the suggestion that this is mostly likely to be a selection of a mild, treatable, non-drug-resistant anaerobic bacteria, sourced from a well-characterised laboratory specimen) with which the cancer patient is purposefully infected and 1 type of drug, matched to be a known effective treatment capable in high doses of eliminating the selected bio-agent from the body or in small doses to moderate the intensity of the infection.
During phase 1 treatment, after purposeful infection with the known mild anaerobic bio-agent, the anti-bio-agent drug is administered but only sufficiently to moderate and limit the intensity and systemic effects of the intended mild infection on the patient yet not overly administered to the point that the bio-agent is destroyed in-vivo before it has it has completed the designed treatment objectives of phase 1 treatment.
In phase 1 of treatment, the expectation would be that the patient’s own immune response will be fighting the bio-agent and so the course of the infection must be monitored and bio-agent and drug doses continuously adjusted to maintain a mild infection.
The objectives of phase 1 treatment
The bio-agent is selected with intention that the infection should establish itself in any anaerobic cores of cancer tumours and be supervised there while the infection attacks and in due course kills those cancerous body cells in any and all anaerobic tumour cores in the patient’s body.
The mild anaerobic bio-agent is selected and managed in-vivo so that it cannot be active, only dormant, in most of the aerobic environments of the body which are routinely supplied with oxygen via the blood, and so an appropriate selection and controlled bio-agent should not harm typical body cells so long as the infection is constrained to be mild with limited systemic effects on the body.
The selected bio-agent is not intended to harm those cancer cells which are growing and dividing in an aerobic environment whether in peripheral parts of all tumours or in aerobic tumour cores which are have grown their own blood supply vessels.
The dangers of a failed phase 1 treatment
Too much bio-agent
Inappropriate selection of a drug-resistant bio-agent, neglecting to moderate the intensity of the infection with sufficient drugs or a patient’s weak immune system failing to eliminate the infection at the conclusion of phase 1 of treatment could lead to a run-away infection causing serious and life-threatening infection or death.
Too little bio-agent
Administering insufficient bio-agent, over-use of drugs or a particularly active immune system could lead to the bio-agent failing to establish itself in all anaerobic tumour cores and a failed attempted phase 1 treatment leaving viable anaerobic tumour cores which would inevitably wreck the hopes for a successful outcome to any attempted phase 2 treatment.
Treatment phase 2
It is proposed that two types of pharmaceutical drug are employed in phase 2 treatment and let’s call them type H drugs ("H" for “Halt cell division!” ) and Type K drugs ("K" for “Kill diving cells”).
Type H drugs - Halt cell division!
At this time, the author does not know if type H drugs are ever used in medicine or indeed are even yet known to medical or biological science. However, this author does not want to wait for that research to be done but rather feels that a “Eureka” moment must be seized and acted upon and the time to publish is now.
Administered on their own, type H drugs are apparently useless medically and apparently harmful so such type H drugs may not have been developed and produced for medical purposes and so may never be available to use medically until someone explains what such drugs could be used for. One of the main points of this paper is to make the case for producing type H drugs so that if they are not now available, the pharmaceutical industry can get busy making them available! What is described here is what H-type drugs are supposed to be able to do.
Type H-drugs utilise and are intended temporarily to saturate the normal cell-signalling pathways which instruct normal cells not to divide. Normal cells with the exception of cancer cells pay heed to such cell to cell signals and it is the defining characteristic of a cancer cell that it ignores such signals not to divide and keeps on dividing regardless.
The purpose of administering a H-type drug is to temporarily overload the normal signals and order an artificial system-wide cessation of all normal cell division in the body. Accordingly, normal cells which frequently divide - skin cells, intestinal wall cells, immune response cells, bone marrow cells, reproductive organ cells etc are tricked into stopping dividing temporarily, so long as the H-type drug is administered.
Type-H drugs operate in a pharmaceutically reversible way and when the H-type drug clears from the body then the normal body cells which have dutifully followed the artificial signals and temporarily ceased dividing then go back to their normal operation without any permanent damage to the cell.
Clearly, the administration of type-H drugs weakens the body systematically which depends on routine cell division and for so long as type H remains in-vivo then harm to the body's health will accumulate.
Type-H drugs don’t do the body any good on their own. Not only that, but for the purpose of treating cancer, type-H drugs do nothing directly to cancer cells either which are oblivious to the cell signalling pathways which type-H drugs are designed to stimulate.
Type K drugs - Kill dividing cells
In order to understand the utility of type-H drugs one has to consider their medical use in conjunction with Type K ( “Kill dividing cells” ) drugs. Type K drugs are known to medical science. They have been used to try to treat cancer but the problem with them is that they tend to kill all dividing cells, not just cancer cells.
OK, well the smarter reader will see by now where we are going with Type H drugs. After administration of a Type H drug which suspends normal cell division but does not affect cancer cell division, the administration of the Type K drug is now a no-brainer. The dividing cancer cells get killed by the Type K drug. The normally dividing cells don’t get killed by the Type K drug because they are no longer dividing thanks to the administration of the Type H drug.
After the dividing cancer cells have died all that remains to be done is to clear the Type K drug from the body while the Type H drug is still in operation. Then later it is safe to discontinue the Type H drug at which point the body will resume normal cell division, free from cancer.
The dangers of a failed phase 2 treatment
The patient will be rendered vulnerable to infectious disease because of the predictable effect of the Type H drug which will prevent parts of the immune system from responding to infections. Worse case of course is that an opportunist infection may kill the patient.
If the Type H drug is not as effective as intended, if the dose is too low, if it is too quickly cleared from the body then the Type K drug will kill normally dividing body cells as well which cripple multiple body functions which depend on dividing cells and worst case kill the patient.
Without a successful phase 1 treatment which has previously killed anaerobic tumour cores, phase 2 treatment will only kill cancer cells dividing in aerobic environments leaving any and all remaining viable anaerobic tumour cores to provide an inexhaustible supply of cancer cells into the aerobic parts of the body. Phase 2 on its own cannot cure cancer; only after a successful phase 1 can it do that.
Conclusion
The Type H drugs are the biggest uncertainly in the author’s mind but if they can be sourced and can work as described then conceptually this looks like an excellent scientific approach and method for the cure of tumorous cancers.
Credits
Thank you to all those from whom I have learned so much.
Dedication
This cure for cancer paper is dedicated to my mother who lives still and to the memory of all my friends and relatives who have died from cancer for whom this cure is too little and too late.
This cure for cancer paper is also dedicated to Condoleezza Rice who has inspired me to understand that I may not be able to control my circumstances as a scientist without employment as such but I can control how I react to my circumstances. Condi’s mother also died from cancer and she has participated in Race for the Cure events.
Prizes.
I do not want the Nobel Prize for Medicine or indeed any Nobel prize so long as Sweden remains governed as a kingdom. I want nothing from the Swedish King nor from any King nor Queen.
I am a republican and only wish to receive prizes, awards or recognition while living or posthumously from republics or at least from non “royal” institutions which find themselves in the unfortunate circumstance of operating as I do inside a country currently governed as a kingdom.
Suggesting a scientific approach and method for the medical treatment of tumorous cancer.
Summary
A scientific approach and method for the medical treatment and cure for tumorous cancer disease is suggested and described.
The desired performance characteristics of suitable types of biological agents and pharmaceutical drugs and an appropriate method of employing those agents and drugs for the treatment and cure of cancer is described.
Caution
Neither the selection of specific agents and drugs, nor the determination of the optimal treatment regimes are described herein because the details for how best to implement the author's general approach and method to cure cancer still require further research by the scientific and medical community which it is hoped this scientific paper will inform and inspire.
So the reader should be cautioned that the author does not herein publish detailed suggestions for oncologists to prescribe for their cancer patients which pills to pop when. The author is a scientist who is trying to find a cure for everyone one day, not a doctor who can cure someone today.
Invitation to informed discussion
This is claimed to be a realistic scientific paper, not a snake-oil-style cure-all claim. This may not be obvious to everyone because I am an amateur independent scientist, neither employed as a scientist, nor published in traditional scientific journals.
I have published widely on the internet on mostly non-scientific topics and I am accustomed to debating my ideas on-line and so I’m quite comfortable inviting replies perhaps as helpful comments and criticisms from fellow scientists and I can also take questions from any cancer specialists, doctors or other informed parties who take an educated interest in such matters.
Approach and method
One type of biological agent and 3 types of drugs are utilised in 2 distinct treatment phases, perhaps with an intermission between phase 1 and phase 2 of the treatment to review that the goals of phase 1 treatment have been reached before moving on to phase 2.
Treatment Phase 1
It is proposed that phase 1 use a mild anaerobic biological agent (with the suggestion that this is mostly likely to be a selection of a mild, treatable, non-drug-resistant anaerobic bacteria, sourced from a well-characterised laboratory specimen) with which the cancer patient is purposefully infected and 1 type of drug, matched to be a known effective treatment capable in high doses of eliminating the selected bio-agent from the body or in small doses to moderate the intensity of the infection.
During phase 1 treatment, after purposeful infection with the known mild anaerobic bio-agent, the anti-bio-agent drug is administered but only sufficiently to moderate and limit the intensity and systemic effects of the intended mild infection on the patient yet not overly administered to the point that the bio-agent is destroyed in-vivo before it has it has completed the designed treatment objectives of phase 1 treatment.
In phase 1 of treatment, the expectation would be that the patient’s own immune response will be fighting the bio-agent and so the course of the infection must be monitored and bio-agent and drug doses continuously adjusted to maintain a mild infection.
The objectives of phase 1 treatment
The bio-agent is selected with intention that the infection should establish itself in any anaerobic cores of cancer tumours and be supervised there while the infection attacks and in due course kills those cancerous body cells in any and all anaerobic tumour cores in the patient’s body.
The mild anaerobic bio-agent is selected and managed in-vivo so that it cannot be active, only dormant, in most of the aerobic environments of the body which are routinely supplied with oxygen via the blood, and so an appropriate selection and controlled bio-agent should not harm typical body cells so long as the infection is constrained to be mild with limited systemic effects on the body.
The selected bio-agent is not intended to harm those cancer cells which are growing and dividing in an aerobic environment whether in peripheral parts of all tumours or in aerobic tumour cores which are have grown their own blood supply vessels.
The dangers of a failed phase 1 treatment
Too much bio-agent
Inappropriate selection of a drug-resistant bio-agent, neglecting to moderate the intensity of the infection with sufficient drugs or a patient’s weak immune system failing to eliminate the infection at the conclusion of phase 1 of treatment could lead to a run-away infection causing serious and life-threatening infection or death.
Too little bio-agent
Administering insufficient bio-agent, over-use of drugs or a particularly active immune system could lead to the bio-agent failing to establish itself in all anaerobic tumour cores and a failed attempted phase 1 treatment leaving viable anaerobic tumour cores which would inevitably wreck the hopes for a successful outcome to any attempted phase 2 treatment.
Treatment phase 2
It is proposed that two types of pharmaceutical drug are employed in phase 2 treatment and let’s call them type H drugs ("H" for “Halt cell division!” ) and Type K drugs ("K" for “Kill diving cells”).
Type H drugs - Halt cell division!
At this time, the author does not know if type H drugs are ever used in medicine or indeed are even yet known to medical or biological science. However, this author does not want to wait for that research to be done but rather feels that a “Eureka” moment must be seized and acted upon and the time to publish is now.
Administered on their own, type H drugs are apparently useless medically and apparently harmful so such type H drugs may not have been developed and produced for medical purposes and so may never be available to use medically until someone explains what such drugs could be used for. One of the main points of this paper is to make the case for producing type H drugs so that if they are not now available, the pharmaceutical industry can get busy making them available! What is described here is what H-type drugs are supposed to be able to do.
Type H-drugs utilise and are intended temporarily to saturate the normal cell-signalling pathways which instruct normal cells not to divide. Normal cells with the exception of cancer cells pay heed to such cell to cell signals and it is the defining characteristic of a cancer cell that it ignores such signals not to divide and keeps on dividing regardless.
The purpose of administering a H-type drug is to temporarily overload the normal signals and order an artificial system-wide cessation of all normal cell division in the body. Accordingly, normal cells which frequently divide - skin cells, intestinal wall cells, immune response cells, bone marrow cells, reproductive organ cells etc are tricked into stopping dividing temporarily, so long as the H-type drug is administered.
Type-H drugs operate in a pharmaceutically reversible way and when the H-type drug clears from the body then the normal body cells which have dutifully followed the artificial signals and temporarily ceased dividing then go back to their normal operation without any permanent damage to the cell.
Clearly, the administration of type-H drugs weakens the body systematically which depends on routine cell division and for so long as type H remains in-vivo then harm to the body's health will accumulate.
Type-H drugs don’t do the body any good on their own. Not only that, but for the purpose of treating cancer, type-H drugs do nothing directly to cancer cells either which are oblivious to the cell signalling pathways which type-H drugs are designed to stimulate.
Type K drugs - Kill dividing cells
In order to understand the utility of type-H drugs one has to consider their medical use in conjunction with Type K ( “Kill dividing cells” ) drugs. Type K drugs are known to medical science. They have been used to try to treat cancer but the problem with them is that they tend to kill all dividing cells, not just cancer cells.
OK, well the smarter reader will see by now where we are going with Type H drugs. After administration of a Type H drug which suspends normal cell division but does not affect cancer cell division, the administration of the Type K drug is now a no-brainer. The dividing cancer cells get killed by the Type K drug. The normally dividing cells don’t get killed by the Type K drug because they are no longer dividing thanks to the administration of the Type H drug.
After the dividing cancer cells have died all that remains to be done is to clear the Type K drug from the body while the Type H drug is still in operation. Then later it is safe to discontinue the Type H drug at which point the body will resume normal cell division, free from cancer.
The dangers of a failed phase 2 treatment
The patient will be rendered vulnerable to infectious disease because of the predictable effect of the Type H drug which will prevent parts of the immune system from responding to infections. Worse case of course is that an opportunist infection may kill the patient.
If the Type H drug is not as effective as intended, if the dose is too low, if it is too quickly cleared from the body then the Type K drug will kill normally dividing body cells as well which cripple multiple body functions which depend on dividing cells and worst case kill the patient.
Without a successful phase 1 treatment which has previously killed anaerobic tumour cores, phase 2 treatment will only kill cancer cells dividing in aerobic environments leaving any and all remaining viable anaerobic tumour cores to provide an inexhaustible supply of cancer cells into the aerobic parts of the body. Phase 2 on its own cannot cure cancer; only after a successful phase 1 can it do that.
Conclusion
The Type H drugs are the biggest uncertainly in the author’s mind but if they can be sourced and can work as described then conceptually this looks like an excellent scientific approach and method for the cure of tumorous cancers.
Credits
Thank you to all those from whom I have learned so much.
Dedication
This cure for cancer paper is dedicated to my mother who lives still and to the memory of all my friends and relatives who have died from cancer for whom this cure is too little and too late.
This cure for cancer paper is also dedicated to Condoleezza Rice who has inspired me to understand that I may not be able to control my circumstances as a scientist without employment as such but I can control how I react to my circumstances. Condi’s mother also died from cancer and she has participated in Race for the Cure events.
Prizes.
I do not want the Nobel Prize for Medicine or indeed any Nobel prize so long as Sweden remains governed as a kingdom. I want nothing from the Swedish King nor from any King nor Queen.
I am a republican and only wish to receive prizes, awards or recognition while living or posthumously from republics or at least from non “royal” institutions which find themselves in the unfortunate circumstance of operating as I do inside a country currently governed as a kingdom.
